Neurodevelopmental disorder therapy
This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73) in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis.
1. A method of treating a neurodevelopmental disorder or multiple sclerosis in a subject by administering to said subject a therapeutically effective amount of a therapeutic agent selected from the group consisting of A2-73, ANAVEX1-41, Anavex19-144 or combinations thereof.
2. The method of claim 1 wherein the neurodevelopmental disorder is Rett syndrome.
3. The method of claim 1 wherein the therapeutic agent is A2-73.
4. The method of claim 3 wherein the therapeutically effective amount of A2-73 is a dosage of from about 0.5 mg/day to about 100 mg/day.
5. The method of any one of claims 3 through 4 wherein said dosage is from about 1 to about 60 mg/day.
6. The method of any one of claims 3 through 5 wherein said dosage is from about 20 to about 50 mg/day.
7. The method of any one of claims 1 through 6 wherein said dosage is administered daily for at least about 10 days.
8. The method of claim 1 wherein the neurodevelopmental disorder is selected from the group consisting of cerebral palsy, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, Smith-Magenis syndrome, and autism spectrum disorder.